Chemistry:Glovadalen
From HandWiki
Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson's disease.[1][2][3][4][5][6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor by 10-fold in vitro with no actions on other dopamine receptors.[5][6] As of May 2024, glovadalen is in phase 2 clinical trials for this indication.[1][2][5] The drug is under development by UCB Biopharma.[1][4][5] It is described as an orally active, centrally penetrant small molecule.[1][5][6]
See also
- List of investigational Parkinson's disease drugs
- DETQ
- Mevidalen
- PF-06412562 (CVL-562)
- Razpipadon (CVL-871)
- Tavapadon (CVL-751)
References
- ↑ 1.0 1.1 1.2 1.3 "UCB 0022". AdisInsight. Springer Nature Switzerland AG. 28 May 2024. https://adisinsight.springer.com/drugs/800063604.
- ↑ 2.0 2.1 "Delving into the Latest Updates on Glovadalen with Synapse". 8 August 2024. https://synapse.patsnap.com/drug/42154ee88f944d1f8b3bdd57dd9521fd.
- ↑ "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update". Journal of Parkinson's Disease 13 (4): 427–439. 2023. doi:10.3233/JPD-239901. PMID 37302040. "Our analysis of dopaminergic therapies shows a continued emphasis on DA agonists and levodopa reformulation. These include Cerevel's tavapadon, a D1/D5 receptor partial agonist and UCB0022, a positive allosteric modulator of the D1 receptor, as well as approaches to sub-cutaneously deliver levodopa/carbidopa such as Abbvie's ABBV-951 and Neuroderm's ND0612.".
- ↑ 4.0 4.1 "Glovadalen". IUPHAR/BPS Guide to PHARMACOLOGY. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=13232.
- ↑ 5.0 5.1 5.2 5.3 5.4 "UCB0022". 3 May 2024. https://www.alzforum.org/therapeutics/ucb0022.
- ↑ 6.0 6.1 6.2 "Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)". Movement Disorders 37 (Suppl 2 [2022 International Congress September 15-18, 2022. Madrid, Spain]). 7 September 2022. https://www.mdsabstracts.org/abstract/preclinical-characterization-of-ucb0022-an-oral-brain-penetrant-selective-clinical-stage-positive-allosteric-modulator-of-the-dopamine-1-receptor-d1-pam/. Retrieved 10 August 2024.
 |  |
